1	Radiation	Radiation	B-NP	NN	O	2	NMOD	0
2	retinopathy	retinopathy	I-NP	NN	O	3	SUB	0
3	is	be	B-VP	VBZ	O	0	ROOT	0
4	treatable	treatable	B-ADJP	JJ	O	3	PRD	0
5	with	with	B-PP	IN	O	4	AMOD	0
6	anti-vascular	anti-vascular	B-NP	JJ	B-protein	10	NMOD	0
7	endothelial	endothelial	I-NP	JJ	I-protein	10	NMOD	0
8	growth	growth	I-NP	NN	I-protein	10	NMOD	0
9	factor	factor	I-NP	NN	I-protein	10	NMOD	0
10	bevacizumab	bevacizumab	I-NP	NN	I-protein	5	PMOD	0
11	(	(	O	(	O	13	DEP	0
12	Avastin	Avastin	B-NP	NN	O	13	DEP	0
13	)	)	O	)	O	10	NMOD	0
14	.	.	O	.	O	3	P	0

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	To	To	B-VP	TO	O	4	VMOD	0
4	report	report	I-VP	VB	O	1	NMOD	0
5	on	on	B-PP	IN	O	4	VMOD	0
6	bevacizumab	bevacizumab	B-NP	NN	O	7	NMOD	0
7	treatment	treatment	I-NP	NN	O	5	PMOD	19	treatment
8	for	for	B-PP	IN	O	7	NMOD	0
9	radiation	radiation	B-NP	NN	O	10	NMOD	0
10	retinopathy	retinopathy	I-NP	NN	O	8	PMOD	0
11	affecting	affect	B-VP	VBG	O	10	NMOD	16	affecting
12	the	the	B-NP	DT	O	13	NMOD	0
13	macula	macula	I-NP	NN	O	11	OBJ	0
14	.	.	O	.	O	4	P	0

1	PATIENTS	PATIENTS	B-NP	NNS	O	3	NMOD	0
2	AND	AND	I-NP	CC	O	3	NMOD	0
3	METHODS	METHODS	I-NP	NNS	O	0	ROOT	0
4	:	:	O	:	O	3	P	0
5	Twenty-one	Twenty-one	B-NP	CD	O	6	NMOD	0
6	patients	patient	I-NP	NNS	O	26	NMOD	0
7	with	with	B-PP	IN	O	6	NMOD	0
8	radiation	radiation	B-NP	NN	O	9	NMOD	0
9	retinopathy	retinopathy	I-NP	NN	O	7	PMOD	0
10	(	(	O	(	O	20	DEP	0
11	edema	edema	B-NP	NN	O	19	NMOD	0
12	,	,	O	,	O	19	P	0
13	hemorrhages	hemorrhage	B-NP	NNS	O	19	NMOD	0
14	,	,	O	,	O	19	P	0
15	capillary	capillary	B-NP	JJ	O	16	NMOD	0
16	dropout	dropout	I-NP	NN	O	19	NMOD	0
17	,	,	O	,	O	19	P	0
18	and	and	O	CC	O	19	NMOD	0
19	neovascularization	neovascularization	B-NP	NN	O	20	DEP	3	neovascularization
20	)	)	O	)	O	9	NMOD	0
21	and	and	O	CC	O	26	NMOD	0
22	a	a	B-NP	DT	O	26	NMOD	0
23	subjective	subjective	I-NP	JJ	O	26	NMOD	0
24	or	or	I-NP	CC	O	26	NMOD	0
25	objective	objective	I-NP	JJ	O	26	NMOD	0
26	loss	loss	I-NP	NN	O	29	SUB	0
27	of	of	B-PP	IN	O	26	NMOD	0
28	vision	vision	B-NP	NN	O	27	PMOD	0
29	were	be	B-VP	VBD	O	3	NMOD	0
30	treated	treat	I-VP	VBN	O	29	VC	0
31	.	.	O	.	O	3	P	0

1	Treatment	Treatment	B-NP	NN	O	2	SUB	0
2	involved	involve	B-VP	VBD	O	0	ROOT	0
3	intravitreal	intravitreal	B-NP	JJ	O	4	NMOD	0
4	injection	injection	I-NP	NN	O	16	NMOD	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	bevacizumab	bevacizumab	B-NP	NN	O	5	PMOD	0
7	(	(	O	(	O	13	DEP	0
8	1.25	1.25	B-NP	CD	O	9	NMOD	0
9	mg	mg	I-NP	NN	O	13	DEP	0
10	in	in	B-PP	IN	O	9	NMOD	0
11	0.05	0.05	B-NP	CD	O	12	NMOD	0
12	mL	mL	I-NP	NN	O	10	PMOD	0
13	)	)	O	)	O	6	NMOD	0
14	every	every	B-NP	DT	O	16	NMOD	0
15	6-12	6-12	I-NP	CD	O	16	NMOD	0
16	weeks	week	I-NP	NNS	O	2	OBJ	0
17	.	.	O	.	O	2	P	0

1	Treatment	Treatment	B-NP	NN	O	2	SUB	0
2	was	be	B-VP	VBD	O	0	ROOT	0
3	discontinued	discontinue	I-VP	VBN	O	2	VC	0
4	at	at	B-PP	IN	O	10	VMOD	0
5	patient	patient	B-NP	NN	O	6	NMOD	0
6	request	request	I-NP	NN	O	4	PMOD	0
7	or	or	B-PP	CC	O	4	PMOD	0
8	if	if	B-SBAR	IN	O	4	PMOD	0
9	there	there	B-NP	EX	O	10	SUB	0
10	was	be	B-VP	VBD	O	3	VMOD	0
11	no	no	B-NP	DT	O	13	NMOD	0
12	measurable	measurable	I-NP	JJ	O	13	NMOD	0
13	response	response	I-NP	NN	O	10	PRD	0
14	to	to	B-PP	TO	O	13	NMOD	0
15	therapy	therapy	B-NP	NN	O	14	PMOD	0
16	.	.	O	.	O	2	P	0

1	Main	Main	B-NP	NNP	O	3	NMOD	0
2	outcome	outcome	I-NP	NN	O	3	NMOD	0
3	measures	measure	I-NP	NNS	O	4	SUB	0
4	included	include	B-VP	VBD	O	0	ROOT	0
5	best	well	B-ADVP	RBS	O	8	NMOD	0
6	corrected	correct	B-NP	VBN	O	8	NMOD	0
7	visual	visual	I-NP	JJ	O	8	NMOD	0
8	acuity	acuity	I-NP	NN	O	17	NMOD	0
9	,	,	O	,	O	17	P	0
10	ophthalmic	ophthalmic	B-NP	JJ	O	11	NMOD	0
11	examination	examination	I-NP	NN	O	17	NMOD	0
12	,	,	O	,	O	17	P	0
13	retinal	retinal	B-NP	JJ	O	14	NMOD	0
14	photography	photography	I-NP	NN	O	17	NMOD	0
15	,	,	O	,	O	17	P	0
16	and	and	O	CC	O	17	NMOD	0
17	angiography	angiography	B-NP	NN	O	4	OBJ	0
18	.	.	O	.	O	4	P	0

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Bevacizumab	Bevacizumab	B-NP	NN	O	4	NMOD	0
4	treatment	treatment	I-NP	NN	O	5	SUB	19	treatment
5	was	be	B-VP	VBD	O	1	NMOD	0
6	followed	follow	I-VP	VBN	O	5	VC	0
7	by	by	B-PP	IN	O	6	VMOD	0
8	reductions	reduction	B-NP	NNS	O	7	PMOD	0
9	in	in	B-PP	IN	O	8	NMOD	0
10	retinal	retinal	B-NP	JJ	O	11	NMOD	0
11	hemorrhage	hemorrhage	I-NP	NN	O	16	NMOD	0
12	,	,	O	,	O	16	P	0
13	exudation	exudation	B-NP	NN	O	16	NMOD	0
14	,	,	O	,	O	16	P	0
15	and	and	O	CC	O	16	NMOD	0
16	edema	edema	B-NP	NN	O	9	PMOD	0
17	.	.	O	.	O	1	P	0

1	Visual	Visual	B-NP	JJ	O	2	NMOD	0
2	acuities	acuity	I-NP	NNS	O	3	SUB	0
3	were	be	B-VP	VBD	O	0	ROOT	0
4	stable	stable	B-ADJP	JJ	O	6	AMOD	0
5	or	or	O	CC	O	6	AMOD	0
6	improved	improve	B-VP	VBN	O	3	VC	0
7	in	in	B-PP	IN	O	6	VMOD	0
8	86	86	B-NP	CD	O	9	NMOD	0
9	%	%	I-NP	NN	O	7	PMOD	0
10	(	(	O	(	O	12	DEP	0
11	n=18	n=18	B-NP	NN	B-protein	12	DEP	0
12	)	)	O	)	O	9	NMOD	0
13	.	.	O	.	O	3	P	0

1	Three	Three	B-NP	CD	O	2	NMOD	0
2	patients	patient	I-NP	NNS	O	3	SUB	0
3	discontinued	discontinue	B-VP	VBD	O	0	ROOT	0
4	therapy	therapy	B-NP	NN	O	3	OBJ	0
5	.	.	O	.	O	3	P	0

1	Each	Each	B-NP	DT	O	2	SUB	0
2	was	be	B-VP	VBD	O	0	ROOT	0
3	legally	legally	B-ADJP	RB	O	4	AMOD	0
4	blind	blind	I-ADJP	JJ	O	2	PRD	0
5	before	before	B-PP	IN	O	2	VMOD	0
6	treatment	treatment	B-NP	NN	O	5	PMOD	0
7	(	(	O	(	O	9	DEP	0
8	n=1	n=1	B-NP	NN	O	9	DEP	0
9	)	)	O	)	O	6	NMOD	0
10	,	,	O	,	O	2	P	0
11	experienced	experience	B-VP	VBD	O	2	VMOD	0
12	little	little	B-NP	JJ	O	11	OBJ	0
13	to	to	B-PP	TO	O	12	NMOD	0
14	no	no	B-NP	DT	O	16	NMOD	0
15	subjective	subjective	I-NP	JJ	O	16	NMOD	0
16	improvement	improvement	I-NP	NN	O	13	PMOD	0
17	(	(	O	(	O	19	DEP	0
18	n=2	n=2	B-NP	NN	O	19	DEP	0
19	)	)	O	)	O	16	NMOD	0
20	,	,	O	,	O	12	P	0
21	or	or	O	CC	O	11	VMOD	0
22	was	be	B-VP	VBD	O	11	VMOD	0
23	poorly	poorly	B-ADJP	RB	O	24	AMOD	0
24	compliant	compliant	I-ADJP	JJ	O	22	PRD	0
25	(	(	O	(	O	27	DEP	0
26	n=2	n=2	B-NP	NN	O	27	DEP	0
27	)	)	O	)	O	24	AMOD	0
28	.	.	O	.	O	2	P	0

1	Three	Three	B-NP	CD	O	2	NMOD	0
2	patients	patient	I-NP	NNS	O	7	SUB	0
3	(	(	O	(	O	6	DEP	0
4	14	14	B-NP	CD	O	5	NMOD	0
5	%	%	I-NP	NN	O	6	DEP	0
6	)	)	O	)	O	2	NMOD	0
7	regained	regain	B-VP	VBD	O	0	ROOT	0
8	2	2	B-NP	CD	O	11	NMOD	0
9	or	or	I-NP	CC	O	11	NMOD	0
10	more	more	I-NP	JJR	O	11	NMOD	0
11	lines	line	I-NP	NNS	O	7	OBJ	0
12	of	of	B-PP	IN	O	11	NMOD	0
13	visual	visual	B-NP	JJ	O	14	NMOD	0
14	acuity	acuity	I-NP	NN	O	12	PMOD	0
15	.	.	O	.	O	7	P	0

1	No	No	B-NP	DT	O	7	NMOD	0
2	ocular	ocular	I-NP	JJ	O	5	AMOD	0
3	or	or	I-NP	CC	O	5	AMOD	0
4	systemic	systemic	I-NP	JJ	O	5	AMOD	0
5	bevacizumab-related	bevacizumab-related	I-NP	JJ	O	7	NMOD	0
6	side	side	I-NP	NN	O	7	NMOD	0
7	effects	effect	I-NP	NNS	O	8	SUB	0
8	were	be	B-VP	VBD	O	0	ROOT	0
9	observed	observe	I-VP	VBN	O	8	VC	0
10	.	.	O	.	O	8	P	0

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Intravitreal	Intravitreal	B-NP	JJ	B-protein	4	NMOD	0
4	bevacizumab	bevacizumab	I-NP	NN	I-protein	5	SUB	0
5	can	can	B-VP	MD	O	1	NMOD	0
6	be	be	I-VP	VB	O	5	VC	0
7	used	use	I-VP	VBN	O	6	VC	0
8	to	to	B-VP	TO	O	9	VMOD	0
9	treat	treat	I-VP	VB	O	7	VMOD	0
10	radiation	radiation	B-NP	NN	O	11	NMOD	0
11	retinopathy	retinopathy	I-NP	NN	O	9	OBJ	0
12	.	.	O	.	O	1	P	0

1	In	In	B-PP	IN	O	0	ROOT	0
2	most	most	B-NP	JJS	O	4	NMOD	0
3	cases	case	I-NP	NNS	O	4	NMOD	0
4	treatment	treatment	I-NP	NN	O	5	SUB	0
5	was	be	B-VP	VBD	O	1	SBAR	0
6	associated	associate	I-VP	VBN	O	5	VC	0
7	with	with	B-PP	IN	O	6	VMOD	0
8	decreased	decrease	B-NP	VBN	O	10	NMOD	0
9	vascular	vascular	I-NP	JJ	O	10	NMOD	0
10	leakage	leakage	I-NP	NN	O	16	NMOD	0
11	,	,	O	,	O	16	P	0
12	stabilization	stabilization	B-NP	NN	O	16	NMOD	0
13	,	,	O	,	O	16	P	0
14	or	or	O	CC	O	16	NMOD	0
15	improved	improve	B-NP	VBN	O	16	NMOD	0
16	vision	vision	I-NP	NN	O	7	PMOD	0
17	.	.	O	.	O	1	P	0

1	An	An	B-NP	DT	O	6	NMOD	0
2	anti-vascular	anti-vascular	I-NP	JJ	B-protein	6	NMOD	0
3	endothelial	endothelial	I-NP	JJ	I-protein	6	NMOD	0
4	growth	growth	I-NP	NN	I-protein	6	NMOD	0
5	factor	factor	I-NP	NN	I-protein	6	NMOD	0
6	strategy	strategy	I-NP	NN	O	7	SUB	0
7	may	may	B-VP	MD	O	0	ROOT	0
8	reduce	reduce	I-VP	VB	O	7	VC	18	reduce
9	tissue	tissue	B-NP	NN	O	10	NMOD	0
10	damage	damage	I-NP	NN	O	8	OBJ	6	damage
11	associated	associate	B-VP	VBN	O	10	NMOD	0
12	with	with	B-PP	IN	O	11	VMOD	0
13	radiation	radiation	B-NP	NN	O	14	NMOD	0
14	vasculopathy	vasculopathy	I-NP	NN	O	16	NMOD	0
15	and	and	I-NP	CC	O	16	NMOD	0
16	neuropathy	neuropathy	I-NP	NN	O	12	PMOD	0
17	.	.	O	.	O	7	P	0

